Evidence map›Paper›PMID 22127890›Full record

ArticleAdvances in experimental medicine and biology2012

Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock.

Yongqing Li, Hasan B Alam

2 registry-linked trialsAbstract read
In one paragraph

Article in Advances in experimental medicine and biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04531579 phase2withdrawnnot on this mapstarted 2022, after this paper: background citation

Evaluation of Valproic Acid (VPA) as Adjunctive Therapy for Trauma Patients With Moderate to Severe Hemorrhage at Risk of Ischemia Reperfusion (I/R) Injury

TypeinterventionalSponsorWestatRan2022 to 2023Enrolled0ConditionsAcute Kidney Injury, Ischemia Reperfusion InjuryArmsValproic Acid Solution, Isotonic saline solution
NCT04531592 phase2withdrawnnot on this mapstarted 2022, after this paper: background citation

Evaluation of Valproic Acid (VPA) as Adjunctive Therapy for Liver Transplant Patients With Moderate to Severe Hemorrhage at Risk of Ischemia Reperfusion (I/R) Injury

TypeinterventionalSponsorWestatRan2022 to 2023Enrolled0ConditionsAcute Kidney Injury, Ischemia Reperfusion InjuryArmsValproic acid, Isotonic saline solution
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Tubastatin A prevents hemorrhage-induced endothelial barrier dysfunction.The journal of trauma and acute care surgery · 2018
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Yongqing LiDepartment of Surgery, Division of Trauma, Emergency Surgery and Surgical Critical Care, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Hasan B Alam
Harvard University · USMassachusetts General Hospital · US

Funding

Modulation of Acetylation in the Treatment of Lethal InjuriesR01GM084127 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALAM, HASAN B · 2009 to 2019
$2.6M
NIGMS NIH HHS R01 GM084127NIGMS NIH HHS R0I GM084127
6 · The paper itself

Abstract

Shock, regardless of etiology, is characterized by decreased tissue perfusion resulting in cell death, organ dysfunction, and poor survival. Current therapies largely focus on restoring tissue perfusion through resuscitation but have failed to address the specific cellular dysfunction caused by shock. Acetylation is rapidly emerging as a key mechanism that regulates the expression of numerous genes (epigenetic modulation through activation of nuclear histone proteins), as well as functions of multiple cytoplasmic proteins involved in key cellular functions such as cell survival, repair/healing, signaling, and proliferation. Cellular acetylation can be increased immediately through the administration of histone deacetylase inhibitors (HDACI). A series of studies have been performed using: (1) cultured cells; (2) single-organ ischemia-reperfusion injury models; (3) rodent models of lethal septic and hemorrhagic shock; (4) swine models of lethal hemorrhagic shock and multi-organ trauma; and (5) tissues from severely injured trauma patients, to fully characterize the changes in acetylation that occur following lethal insults and in response to treatment with HDACI. These data demonstrate that: (1) shock causes a decrease in acetylation of nuclear and cytoplasmic proteins; (2) hypoacetylation can be rapidly reversed through the administration of HDACI; (3) normalization of acetylation prevents cell death, decreases inflammation, attenuates activation of pro-apoptotic pathways, and augments pro-survival pathways; (4) the effect of HDACI significantly improves survival in lethal models of septic shock, hemorrhagic shock, and complex poly-trauma without need for conventional fluid resuscitation or blood transfusion; and (5) improvement in survival is not due to better resuscitation but due to an enhanced ability of cells to tolerate lethal insults.As different models of hemorrhagic or septic shock have specific strengths and limitations, this chapter will summarize our attempts to create "pro-survival and anti-inflammatory phenotype" in various models of hemorrhagic shock and septic shock.

Indexed as

PhenotypeSurvival RateAcetylationAnimalsDisease Models, AnimalEpigenesis, GeneticHistone Deacetylase InhibitorsMitogen-Activated Protein KinasesParacrine CommunicationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReperfusion InjuryShock, HemorrhagicShock, SepticSignal TransductionToll-Like Receptor 4Histone Deacetylase InhibitorsMitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktToll-Like Receptor 4

Identifiers

PMID22127890
PMCPMC4894314
OpenAlexW179704473

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.